2 terminated, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow CH5183284: new trials by email Literature Review of CH5183284 trials Research Report on CH5183284
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) Debio 1347 - Solid Tumor | Phase 2 | Terminated | Debiopharm International SA | 63 | 2019-03-22 | 2024-02-07 |
| A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer Fulvestrant, Debio 1347 - Breast Cancer | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2017-11-10 | 2022-11-25 |
| Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations Debio1347 (CH5183284) - Solid Tumours | Phase 1 | Terminated | Debiopharm International SA | 77 | 2013-08-01 | 2020-09-09 |
Breast Neoplasms (1)
Debiopharm International SA (2) · Memorial Sloan Kettering Cancer Center (1)
United States (3) · Singapore (2) · South Korea (2) · Spain (2) · Taiwan (2) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Croatia (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Greece (1)
2018 (1)